Ernexa Therapeutics Inc. — Director's Dealing 2021

Jun 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Brooklyn ImmunoTherapeutics, Inc. (BTX)
CIK: 0000748592
Period of Report: 2021-06-16

Reporting Person: Cherington Charles (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-16	Common Stock	S	200000	$15.7338	Disposed	6094101	Direct
2021-06-17	Common Stock	S	198000	$15.7435	Disposed	5896101	Direct
2021-06-17	Common Stock	S	2000	$16.2974	Disposed	5894101	Direct

Footnotes

F1: The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.53 to $16.11, inclusive.

F2: The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.25 to $16.24, inclusive.

F3: The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.35, inclusive.